HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for BridgeBio Pharma, maintaining a price target of $43.
September 30, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for BridgeBio Pharma, maintaining a price target of $43, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $43 price target by HC Wainwright & Co. suggests a positive outlook for BridgeBio Pharma. This can lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100